CIK 0001347178
- Accelerated filer
Vanda Pharmaceuticals Inc.
Sign in to watch- Ticker
- VNDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 030491827
- Phone
- +1 202-734-3400
- Business address
- 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, 20037
- 4 Open-market sale President and CEO sold 55,172 shares at an average $4.19 ($231,339)
- 4 Open-market sale SVP, CFO & Treasurer sold 14,700 shares at an average $4.31 ($63,393)
- 4 Open-market sale SVP, Business Development sold 17,411 shares at an average $4.21 ($73,379)
- 4 Grant or award SVP & General Counsel acquired 125,000 shares (grant or award)
- 4 Grant or award SVP, Chief Marketing Officer acquired 32,700 shares (grant or award)
- 4 Grant or award SVP, CFO & Treasurer acquired 125,000 shares (grant or award)
- 4 Grant or award President and CEO acquired 450,000 shares (grant or award)
- 4 Grant or award SVP, Business Development acquired 125,000 shares (grant or award)
- 4 Open-market sale SVP, Chief Marketing Officer sold 3,724 shares at $5.84 ($21,748)
- 4 Open-market sale Director sold 6,500 shares at $6.05 ($39,349)
- 4 Open-market sale SVP, CFO & Treasurer sold 2,212 shares at an average $6.30 ($13,945)
- 4 Open-market sale SVP, CFO & Treasurer sold 16,000 shares at $6.29 ($100,710)
- 4 Open-market sale SVP & General Counsel sold 14,600 shares at $6.56 ($95,754)
- 4 Grant or award Director acquired 17,307 shares (grant or award)
- 4 Grant or award Director acquired 17,307 shares (grant or award)
- 4 Grant or award Director acquired 17,307 shares (grant or award)
- 4 Grant or award Director acquired 17,307 shares (grant or award)
- 4 Grant or award Director acquired 17,307 shares (grant or award)
- 4 Grant or award Director acquired 26,408 shares (grant or award)
- 3 Insider Initial Statement of Ownership
Page 4 of 29 · 579 filings